Molecular profiling to predict chemosensitivity for osteosarcoma
Project/Area Number |
23791673
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Orthopaedic surgery
|
Research Institution | Chiba Cancer Center (Research Institute) |
Principal Investigator |
IWATA Shintaro 千葉県がんセンター(研究所), 医療局 整形外科, 主任医長 (90549685)
|
Co-Investigator(Renkei-kenkyūsha) |
大平 美紀 千葉県がんセンター研究所, がんゲノム研究室長 (20311384)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 骨肉腫 / CGH / 薬剤感受性 / ゲノム / 次世代シーケンサー / ゲノム解析 / 次世代シーケンシング / アレイCGH |
Research Abstract |
Chemosensitivity is the most important prognostic factor for osteosarcoma (OS). We have carried out our project to identify possible genomic markers for the prediction of chemosensitivity for pediatric OS patients using CGH technique. 22 tumor samples of pediatric conventional OS patients who divided into three groups according to the histological response to chemotherapy were applied. Differential aberration analyses resulted that 8 putative genomic markers harboring OS-related genes were selected for classifying each 3 groups. Scoring system to predict chemosensitivity was developed with these genomic markers and validation analysis with 8 independent patients confirmed that the scoring system was remarkably consistent to the patient properties. These signatures may be useful for the prediction of chemosensitivity and validation with more samples is awaited.
|
Report
(4 results)
Research Products
(19 results)